https://ojs3.relawanjurnal.id/index.php/JTI <p><strong>JTI </strong>Diterbitkan oleh Universitas Latihan</p> en-US <p>ini contoh isi CN</p> putralar@gmail.com (Putra Maha Surya) aguss0896@gmail.com (Andi Agus Salim) Mon, 29 Nov 2021 09:49:15 +0700 OJS 3.1.2.4 http://blogs.law.harvard.edu/tech/rss 60 https://ojs3.relawanjurnal.id/index.php/JTI/article/view/91 <p><strong>Background: </strong>BCR-ABL1 fusion gene, which originated from t (9;22), is an important biomarker for diagnosis, therapeutic approach, and prognosis in childhood leukemia. However, there are no data in Indonesia about the profile of BCR-ABL1 fusion gene for this disease. This study intends to demonstrate the profile of the BCR-ABL1 fusion gene in childhood leukemia at “Dharmais” Cancer Center Hospital.</p> <p><strong>Methods: </strong>This descriptive retrospective study included 79 patients with childhood leukemia who performed the BCR-ABL1 examination in “Dharmais” Cancer Center Hospital during 2008–2018. Demographic data, leukemia types, BCR-ABL1 examination results, and protein isoforms developed by BCR-ABL1 fusion were obtained from Cancer Registry Data.</p> <p><strong>Results: </strong>Among 79 patients’ data recorded in this study, 65.8% (52/79) were male and 34.2% (27/79) were female. A total of 74.7% (59/79) patients were diagnosed with Chronic Myelogenous Leukemia (CML), 21.5% (17/79) with Acute Lymphoblastic Leukemia (ALL), and 3.8% (3/79) with Acute Myelogenous Leukemia (AML). The profile of positive BCR-ABL1 in CML patients was 72.8% (43/59). About 97.7% (42/43) of CML patients with positive BCR-ABL1 fusion gene expressed 210-kDa protein, while only 2.3% (1/43) expressed 190-kDa protein.</p> <p><strong>Conclusions: </strong>This study found that, from a total of 79 respondents, 45 of them showed a positive BCR-ABL result, with details of 43 in CML and 2 in ALL. Among the total of 43 CML patients with positive BCR-ABL1, 42 (97.7%) of them expressed 210-kDa protein isoform. Further research to investigate the relationship between protein isoforms and their clinical effects may also be important to discuss. The valuable recommendation suggests that BCR-ABL1 examination should be performed for all childhood leukemia patients in Indonesia, especially for CML and ALL.</p> Puji Lestari Copyright (c) 2021 Puji Lestari https://creativecommons.org/licenses/by-sa/4.0 https://ojs3.relawanjurnal.id/index.php/JTI/article/view/91 Mon, 29 Nov 2021 09:40:18 +0700